|55 Kenosia Avenue
Danbury, CT 06810
Toll Free: 1.800.999.6673
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
Copyright 1987, 1988, 1990, 1992, 1997, 2004
Glutaricaciduria II is one of the conditions termed organic acidemias. Individuals with these conditions have a deficiency or absence of an enzyme that prevents them from breaking down certain chenicals in the body, resulting the accumulation of several organic acids in the blood and urine. Two enzymes that may be deficient in glutaricaciduria II are electron transfer flavoprotein (ETF) and ETF-ubiquinone oxidoreductase (ETF:QO). A complete enzyme deficiency causes a severe form of the disorder termed neonatal glutaricaciduria ll that is associated with a short life span and, sometimes, with specific physical birth defects. The less severe form of the disorder is termed late onset glutaricaciduria ll and has an extremely variable age of onset. Symptoms include nausea, vomiting, weakness and low blood sugar (hypoglycemia). Glutaricaciduria II is inherited as an autosomal recessive genetic disorder.
Newborns with the neonatal form of the disorder may have severe hypoglycemia, respiratory distress, low muscle tone, an odor of sweaty feet, liver abnormalities (hepatomegaly) and kidney abnormalities. Physical abnormalities are sometimes present and can include a large head (macrocephaly), high forehead, flat nasal bridge, malformed ears and genital abnormalities.
Symptoms of the late onset form of the disorder are variable and may include hypoglycemia and intermittent periods of vomiting and weakness.
Glutaricaciduria ll is caused by a deficiency or absence of enzymes that break down fats and proteins in the body, resulting in the accumulation of several organic acids in the blood and urine. Two enzymes that have been associated with glutaricaciduria II are electron transfer flavoprotein (ETF) and EFT-ubiquinone oxidoreductase (ETF:QO). Some individuals with glutaricaciduria ll have normal levels of these enzymes and the abnormal enzyme in those patients is not known.
Glutaricaciduria ll is inherited as an autosomal recessive genetic trait. Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.
Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.
No reliable data exist on the incidence of this condition.
Glutaricaciduria I is a rare hereditary metabolic disorder caused by a deficiency of the enzyme glutaryl-CoA dehydrogenase. The disorder is characterized by decreased muscle tone (hypotonia), vomiting, and acidity of the blood. The patient may have involuntary movements of the trunk and limbs (dystonia or athetosis), and mental retardation may also occur. (For more information on this disorder, choose "glutaricaciduria I" as your search term in the Rare Disease Database.)
Medium chain CoA dehydrogenase deficiency (MCAD) is a very rare metabolic disorder characterized by a deficiency of the enzyme CoA dehydrogenase. This enzyme is needed in the breakdown (metabolism) of fats. Low blood sugar (hypoglycemia), lack of energy (lethargy) and possibly coma, associated with fatty changes in the liver, usually occur. During hypoglycemic periods, tests usually show massive amounts of dicarboxylic acid in the urine.
There are many rare disorders caused by enzyme deficiencies. To locate these disorders on the Rare Disease Database, choose "enzyme deficiency" as your search term.
The diagnosis of glutaricaciduria ll is usually made by examining urine organic acids. The characteristic pattern for glutaricaciduria is an elevation of glutaric, ethylmalonic, adipic and isovaleric acid. Some individuals with this condition are initially identified through newborn blood screening using tandem mass spectrometry for the markers C4, C5, C6, C8 and C10. Some individuals do not have an abnormal pattern of urine organic acids except when they are ill. The definitive diagnosis of glutaricaciduria ll is made by demonstrating abnormalities in ETF or ETF-QO antigens or activity in cultured fibroblast cells obtained from a skin biopsy. Prenatal diagnosis may be possible by measuring glutaric acid in amniotic fluid.
Glutaricaciduria is usually treated with a high carbohydrate, low protein and low fat diet. It is recommended that affected individuals eat often to avoid low blood sugar. Dietary supplementation with riboflavin, glycine and carnitine may be helpful.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
176 Nantwich Road
Crewe, CW2 6BG United Kingdom
Phone #: 440-845-2412173
800 #: N/A
Home page: http://www.CLIMB.org.uk
PO Box 54
Okemos, MI 48864 USA
Phone #: 517-381-1940
800 #: --
Home page: http://www.fodsupport.org
PO Box 8126
Gaithersburg, MD 20898-8126
Phone #: 301-251-4925
800 #: 888-205-2311
Home page: http://rarediseases.info.nih.gov/GARD/
1A Whitley Close
Cheshire, CW10 0NQ United Kingdom
Phone #: 016-068-3719
800 #: --
Home page: N/A
5, Saxon Road
Middlesex, TW15 1QL United Kingdom
Phone #: 440-178-4245989
800 #: --
Home page: http://myweb.tiscali.co.uk/priddy/
P.O. Box 1008
Pinole, CA 94564 USA
Phone #: 763-559-1797
800 #: --
Home page: http://www.oaanews.org/index.htm
Brusilow SW, Vallee DL. Symptomatic inborn errors of metabolism in the neonate. Current Therapy in Neonatal-Perinatal Medicine. Marcel Decker. 1985;24-27.
FROM THE INTERNET
McKusick VA. Online Mendelian Inheritance in Man, 6th ed. Johns Hopkins University Press; 1983:703,735,1038.
Report last updated: 2008/05/10 00:00:00 GMT+0